RSS Feed
Cosmetic Surgery Stocks Keep Stiff Upper Lip
Allergan, Mentor and Medicis have struggled in the past year, but if the economy improves, share prices could, too.
Related Topics: Health Care | Drugs
05:05PM 10/28/08
For Abbott, Diversity Remains Paramount
When it comes to investing in big pharmaceutical stocks, it's hard to top this company, especially as its peers continue to suffer.
Related Topics: Health Care | Drugs
01:06PM 08/21/08
Legal Questions Still Dogging Wyeth
The company continues to wrestle with the dilemma surrounding the drugs Premarin, Prempro and Premphase. Plaintiffs' lawyers have filed approximately 5,400 lawsuits.
Related Topics: Drugs | Health Care
12:37PM 07/21/08
Baxter International Hiding in Plain Sight
In the past five years, its stock has more than tripled, easily outperforming the S&P 500 and the Amex Index of large drug stocks. Is anyone paying attention?
Related Topics: Health Care | Drugs
06:59AM 07/01/08
Generic-Drug Stocks Still Under the Weather
Shares of most major generic-drugmakers have traded below the S&P 500 for the 12 months ended May 23, and that index was off nearly 10%.
Related Topics: Health Care | Drugs
01:40PM 06/05/08
Need Defense? Think Medical Supplies
Companies such as C.R. Bard and Becton Dickinson might not be the most glamorous names, but their slow and steady performances may win the race.
Related Topics: Health Care | Stock Picks
06:44AM 04/11/08
The Real Winners of Drug Experimentation
The companies that supply the tools needed for pharma research and development often profit no matter the success of a drug trial.
Related Topics: Health Care | Drugs | Biotech
06:59AM 04/03/08
A Safer Way to Play the Drug Sector
Contract research organizations aren't without risks of course, but they do offer some protection against the vagaries of the industry.
Related Topics: Drugs | Health Care
06:16AM 02/26/08
Schering-Plough's Adjusted Profits Top Estimates
Shares rise 5.4% on the news.
Related Topics: Health Care | Drugs
02:56PM 02/12/08
Reasons to Believe in Schering-Plough
Despite the Vytorin setback, the focus here should be on drugs in development, not products in the market.
Related Topics: Stock Picks | Health Care | Drugs
02:05PM 02/11/08
Find more premium investing ideas